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Abstract Clinical use of DC BeadTM loaded with dox-
orubicin (DEBDOXTM) or irinotecan (DEBIRITM), for the
treatment of primary and secondary tumours of the liver
respectively, is showing great promise. Recently there has
been a tendency to select smaller bead size ranges to treat
tumours in an effort to allow more drug dose to be admin-
istered, improve tumoural penetration and resultant drug
delivery and tumour coverage. Herein we describe the
development and performance characterisation of a new DC
Bead size range (DC BeadM1TM, 70–150 lm) capable of an
increased bead delivery in the distal vasculature, corre-
sponding to greater tumour coverage and drug dose deliv-
ered. Both unloaded and drug loaded DC BeadM1 were
shown to have a greater density of distal volume of pene-
tration although the ultimate distal level of penetration was
the same as that of the 100–300 lm beads in an in vitro
penetration model. Elution of doxorubicin was slower than
irinotecan elution, but it was similar when comparing the
same drug elution from 70 to 150 lm compared to
100–300 lm beads. Radiopaque versions of 70–150 and
100–300 lm beads were prepared in order to evaluate dis-
tribution ex vivo using l-CT and doxorubicin distribution
using epifluorescent microscopy. Liver distribution of the
radiopaque versions of the beads was shown to be more
distal and efficient at filling smaller vessels with the DC
BeadM1 and correspondingly more beads were found per
vessel histologically with a larger area of drug coverage with
the smaller size range. This study indicates that the smaller
(70–150 lm) beads should permit an increased dose of drug
to be administered to both hypervascular and hypovascular
tumours as compared to 100–300 lm beads.
1 Introduction
Transarterial chemoembolisation (TACE) has been prac-
ticed in patients for over 3 decades [1, 2] and describes the
targeted delivery of chemotherapeutic agents followed by
embolic material(s) to hypervascular liver tumors through a
catheter placed in the tumor supplying arteries [3].
Although there is no worldwide standard technique [4],
conventional TACE (cTACE) is most often performed by
emulsifying chemotherapeutics with Lipiodol and then
infusing this emulsion through the catheter prior to delivery
of the embolic material. More recently, drug-eluting bead
TACE (DEB-TACE) has emerged as an alternative to
cTACE [5]. In DEB-TACE, calibrated size ranges of
embolic microspheres are loaded with a drug and then
delivered in a single image-guided step. Although use of
DEB-TACE has recently increased, clinical practice is still
evolving with regard to technique and material choice.
The most commonly used [4] and well characterised
DEB is DC Bead, which is a microspherical embolisation
device composed of acrylamido polyvinyl alcohol–co–
acrylamido-2-methylpropane sulfonate capable of loading
and eluting positively-charged drugs such as doxorubicin
or irinotecan via an ion exchange process [6–11]. TACE
using DC Bead loaded with doxorubicin (DEBDOX) has
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become a popular treatment option for patients with
intermediate stage hepatocellular carcinoma (HCC), a
highly vascular liver tumour [12]. The first phase I/II
DEBDOX studies of Varela et al. [13] and Poon et al. [14]
involved a dose-escalation phase and used DEBs measur-
ing 500–700 lm in diameter. This particular size range was
a consequence of the direct translation of the embolic agent
size historically used to treat these patients using cTACE
methods, which often used non-spherical embolic agents
such as polyvinyl alcohol (PVA) particles to complete the
embolisation after delivery of the chemotherapy emulsion.
The choice of embolic agent size is an important con-
sideration and should be suited to the physicians’ desired
level of occlusion, but in addition to size, embolic material
composition must also be considered as compressibility of
microspheres plays a role in the level of occlusion [15, 16].
Whilst the doxorubicin dosage administered in clinical
practice has remained consistent at 100–150 mg per-treat-
ment, there has been a subtle migration to using progres-
sively smaller DEB sizes. This is illustrated in the
published literature, such as the first PRECISION I and II
studies which used solely 500–700 lm DC Bead [13, 14],
with the later randomized phase II trial PRECISION V [17]
and the study of Dhanasekaran et al. [18] which recom-
mended use of 300–500 lm and 500–700 lm DC Bead;
and those of Malagari et al. [19–21] and Reyes et al. [22]
for instance, which used 100–300 lm and 300–500 lm
sized products in treatment of HCC. More recent consensus
recommendations suggest use of 100–300 lm DEBs [23].
In addition to DEBDOX, the combination of irinotecan
with DC Bead (DEBIRI) is an attractive locoregional ther-
apy for some patients with liver metastates from colorectal
cancer (mCRC). DEBIRI has shown benefit in patients for
whom systemic chemotherapy options have failed and in
whom surgical resection is not possible [24–26], as well as
those in whom tumor shrinkage is required to allow surgical
resection i.e., surgical down-staging and neo-adjuvant
therapy [27]. Irinotecan is chosen over doxorubicin in
treatment of mCRC due to its common use in an effective
systemic combination chemotherapy regimen called FOL-
FIRI [28]. Although mCRC may be hypervascular relative to
the liver, these tumors tend to be less vascularized than HCC
and this difference in vascularity can limit the volume of
DEBs and irinotecan that can be delivered to the tumour
using DEBIRI. Moreover, mCRC often results in multiple
and diffuse tumours in the liver requiring a more proximal
catheter placement into the right or left hepatic artery fol-
lowed by a lobar infusion of DEBIRI [26]. These factors
motivated the preference of 100–300 lm beads for treatment
of mCRC [29], as this was the smallest size commercially
available at the time of study initiation for DEBIRI and more
often allowed for a greater volume of beads and irinotecan to
be delivered to the patient.
The desire for improved penetration must be balanced
with potential safety concerns associated with use of very
small microspheres. There have been isolated cautionary
reports of potentially fatal complications from non-target
embolisation following the use of small embolic agents,
such as 40–120 lm sized trisacryl microspheres or 40 lm
polyphosphazene coated PMMA microspheres [30, 31].
However, it is now generally accepted that appropriate use
of careful angiographic analysis for shunting if using small
deformable hydrogel microspheres can ameliorate this
safety concern associated with the use of smaller devices.
A smaller DEB has therefore been developed for use in
DEBDOX or DEBIRI, which might provide the benefits of
a smaller size range including a greater distal penetration,
access to tumour regions perfused with small diameter
blood vessels, and provide a higher dose of drug delivered
to the target tissue, whilst minimising the associated
potential safety risks. This overview compares the in vitro
and in vivo performance characteristics of 70–150 lm
DEBs with the established DEB size ranges and discusses
some of the outcomes from its use in clinical practice.
2 Materials and methods
The different bead size ranges were subjected to drug
loading and elution studies using both doxorubicin and
irinotecan, and the effects of drug loading on bead size and
penetration potential evaluated. In order to appreciate the
differences in bead distribution in tissue, radiopaque ver-
sions of the beads were used to render them visible under
X-ray imaging.
2.1 Bead materials
DC Bead M1 (70–150 lm) and DC Bead (100–300 lm,
300–500 lm, and 500–700 lm) (Biocompatibles UK
Limited, a BTG International group company Farnham,
UK) are composed of acrylamido polyvinylalcohol-co-
acrylamido-2-methylpropane sulfonate. Vials containing
2 mL of sedimented bead volume were used for in vitro
characterization. To enable in vivo bead distribution stud-
ies to be performed and imaged using lCT, radiopaque
versions of DC BeadM1 (radiopaque 70–150 lm) and DC
Bead 100–300 lm (radiopaque 100–300 lm) were pre-
pared as previously described [32]. Briefly, beads were
lyophilised and incorporated with iodized oil and doxoru-
bicin using a previously reported process [33].
2.2 Bead drug loading
Two mLs (one vial) of 70–150 and 100–300 lm beads
were loaded with either 50 mg/mL or 75 mg/mL of
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doxorubicin hydrochloride (Dabur, India), or 100 mg/mL
of irinotecan hydrochloride trihydrate (Dabur, India) via an
ionic exchange mechanism. The packing solution was
removed from the vial to leave a slurry of beads to which a
sterile water drug solution was added and drug uptake
determined by measurement of the depleted loading solu-
tion at set time intervals by UV–Visible spectrophotometry
as previously reported [9, 10]. The resulting drug eluting
beads (DEB) loaded with doxorubicin or irinotecan were
suitable for in vitro characterization studies.
2.3 Bead sizing
Bead sizes were measured using a BX50 microscope and a
910 dry objective. (Olympus UK Ltd, Essex, England). To
verify the eyepiece graticule used to measure the beads, a
calibrated graticule (Graticules Ltd, Kent, England) was
placed on the microscope stage and the eyepiece divisions
verified. A monolayer of each type of bead (fully hydrated
in 0.9 % saline) was placed in a Petri dish on the micro-
scope stage. Using the 910 objective the diameter of 200
individual beads was measured using the eyepiece gratic-
ule. The microscope stage was moved systematically
across the sample to ensure no repeat measurement of
individual beads. The bead sizing data was entered into a
spreadsheet and the data graphs generated using Prism 6
(GraphPad Software, Inc., La Jolla, CA).
2.4 Bead penetration studies
Figure 1 shows a schematic of the experimental set-up of
an apparatus designed to measure bead penetration poten-
tial. A cut-out section of tapering depth was milled into a
block of Delrin and a glass plate secured over the cut-out
section to create a wedge geometry with a depth of 555 lm
at one end and 25 lm at the other. The carrier fluid (saline)
was held in a reservoir and connected to the plate assembly
via an entry port at the wider end of the plate assembly; the
pressure under which the fluid flows was controlled by the
hydrostatic pressure created when the reservoir was raised
54.4 cm above the penetration device resulting in
*40 mmHg to emulate circulatory blood pressure in
appropriately sized vessels (hepatic pressure varying from
90 mmHg in the hepatic artery to 10 mmHg in the sinu-
soids and the beads generally residing in vessels mid-size
to these extremes [34] ).
A bead slurry of between 0.1 and 0.5 mL of sedimented
beads (depending on the size being analysed) was intro-
duced via an injection port into the carrier fluid line,
whereby the fluid flow (under 40 mmHg hydrostatic pres-
sure) carried the beads into the plate assembly until they
were physically constrained by their size and could not
migrate further into the narrowing gap. A picture of the
plate assembly was captured using a digital camera and the
bead blocking point and distribution of beads throughout
the plate assembly noted.
2.5 Drug elution using pseudo-sink conditions
Amber jars each containing 500 mL of PBS with a mag-
netic stir bar were placed in a heated water bath which was
on the top of two magnetic stirrer plates. The temperature
of the PBS elution medium was controlled at 37 C by pre-
equilibrating the system overnight. Before elution, the drug
loaded microsphere samples were brought up to room
temperature from refrigerated conditions, and the depleted
solution was removed completely. 25 mL of PBS from the
elution jar was taken to rinse all the drug-loaded beads into
the elution jar. Time zero was defined as when the first
sample was placed into the elution media. At each sam-
pling time-point, a 200 mL volume of PBS medium (ex-
cept for 5 mL at the first sampling time point only) was
removed from the jar through a cannula filter, followed by
adding back the same volume of fresh PBS to ensure
pseudo-sink conditions were maintained. From this with-
drawn aliquot, approximately 5–10 mL of eluted sample
was used for UV analysis. Absorbance of the eluted sample
was measured at 483 nm and 369 nm on a UV–Vis spec-
trophotometer for doxorubicin and irinotecan respectively.
2.6 Demonstration of bead distribution in vivo
as a function of size
All animal studies were conducted under an animal use
protocol approved by an NIH Animal Care and Use
Committee. VX2 tumours were propagated as described
by Ranjan et al. [35]. Briefly, VX2 was propagated in the
hind limb of donor rabbits as a single cell suspension.
Fragments of these tumours were percutaneously injected
into a liver under ultrasound guidance and monitored with
ultrasound for 2–3 weeks until a VX2 hepatic tumour of
diameter greater than 1 cm in any dimension was estab-
lished [36].
This rabbit Vx2 intrahepatic tumor model was used to
compare the penetration of 70–150 lm with 100–300 lm
radiopaque beads after transcatheter embolisation. After
induction of anesthesia with ketamine (20 mg/kg; Bedco,
St. Joseph, MO), Acepromazine (0.75 mg/kg; Bedco), and
Glycopyrolate (1.2 mg; Baxter Healthcare, Dearfield, IL),
animals were maintained under general anesthesia with
isoflurane. Ketoprofen (5 mg; Fort Dodge Animal Health,
Fort Dodge, IA) was given intramuscularly during induc-
tion to provide additional analgesia. Femoral access and
catheter placement in the proper hepatic artery was con-
ducted with a 3F sheath (Cook, Bloomington, IN) and a 2.4
Fr microcatheter (Terumo, Somerset, NJ) under
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fluoroscopic guidance. Routine fluoroscopy was conducted
using the 9900 Elite Digital Mobile Super C-arm (GE
Healthcare/OEC Medical Systems, Inc., Waukesha, WI).
Radiopaque beads were mixed 1:20 in saline/Isovue 300
contrast and delivered under fluoroscopic monitoring at a
rate of approximately 1 ml/min (including agitation time)
until an endpoint of stasis in the proper hepatic artery was
angiographically determined. Fluoroscopic images of the
targeted organ were obtained intermittently throughout the
embolisation and the animal was euthanised 5 min after the
completion of embolisation. Following euthanasia, liver
and tumor tissue was harvested, placed in formalin and
stored at 4 C prior to ex vivo analysis.
Harvested liver tissue was imaged on 256 slice CT
(Philips Healthcare, Best, The Netherlands) with the fol-
lowing settings: 465 mAs, 80 keV, 1 mm thickness,
0.5 mm overlap (typical clinical abdominal scan without
contrast) and also 625 mAs, 120 keV, 0.67 mm thickness,
0.335 mm overlap (internal auditory canal (IAC) scan). To
resolve individual radiopaque beads within tissue an
Inveon microCT (Siemens Preclinical Solutions, Knox-
ville, TN) was used with the following settings: 31 lm
resolution, 80 keV, tube current of 380 lA and a 2 mm
Aluminum filter. Images are displayed as 3-dimentional
renderings and maximum intensity projections (MIPs) with
an arbitrary window and level to maximize contrast.
The data shown for the swine liver embolisation in the
discussion were generated according to the methods
described in Dreher et al. [37].
2.7 Statistics
Statistical analysis was performed with GraphPad Prism 6.05
(GraphPad Software Inc., La Jolla, CA). Bead size distribu-
tions were analysed with descriptive statistics using a relative
frequency distribution with a pre-defined bin width. Drug
elution was analysed for half-life using first-order (irinotecan)
or second order (doxorubicin). Maximum bead penetration
was analysed with a two-way ANOVA with factors bead size
and drug loading (post hoc analysis with Tukey’s multiple
comparison test). All P-values were two-sided and values
\0.05 were considered statistically significant.
3 Results
3.1 Drug loading characteristics
The rate of drug uptake is known to increase with a
decrease in the size of the beads due to an increased surface
area to volume [8]. Drug loading of the 70–150 lm range
was observed to be only slightly faster than the
100–300 lm size range for doxorubicin and very similar
for irinotecan (see Table 1).
3.2 Bead size
The smaller bead size (70–150 lm) was obtained by
additional sieving to remove the larger bead size fraction
Fig. 1 Penetration model
schematic. Beads are introduced
at the wide end of the taper and
flow under the hydrostatic
pressure until they block in a
band commensurate with their
size and mechanical properties
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found in the 100–300 lm size range as shown in Figs. 2
and 3. The beads appear similarly smooth and spherical in
shape but the 70–150 lm is more uniform in bead size
distribution. Both bead sizes are capable of loading
irinotecan (Fig. 2c, d) and doxorubicin (Fig. 2e, f) resulting
in a corresponding decrease in the average diameter of the
beads due to water displacement and drug interactions [8]
as clearly shown in optical micrographs of Fig. 2 and
graphically Fig. 3b. For the 100–300 lm beads there is a
percentage decrease in the average size in the range of 7,
12 and 24 % when loaded with either 25 mg/mL doxoru-
bicin, 37.5 mg/mL doxorubicin or 50 mg/mL irinotecan
respectively. For the 70–150 lm beads the percentage
decrease is relatively greater at 14, 25 and 28 % respec-
tively for the same drug doses (see Fig. 3b).
3.3 In vitro penetration properties
Bead penetration was quantified with a custom penetration
model, shown in Fig. 1, which created a wedge geometry
that decreased in gap size in the direction of flow.
Interestingly, the more narrow size distribution in the
70–150 lm beads results in a more uniform leading edge
while the other bead sizes have a more sporadic appearance
where some larger beads in the distribution decrease the
penetration of subsequent smaller beads. There was a sig-
nificant effect of bead size and drug loading on the maxi-
mum penetration (P value \0.05, 2 way ANOVA).
Importantly, the average bead penetration was not different
for 70–150 and 100–300 lm (P value[0.05, Tukey’s) but
significant for all other comparisons with 300–500 lm
(P value \0.05, Tukey’s). Doxorubicin and irinotecan
loading significantly increased the penetration for all bead
sizes (P value \0.05, Tukey’s) except 100–300 lm with
irinotecan.
When loaded with drug, as shown in Fig. 4, trends are
similar to bland beads with a nearly identical leading edge
between size ranges but on average a much greater pene-
tration and uniformity for the smaller size range. These
data suggest the reduction in size due to drug loading is
balanced by an increase in stiffness, resulting in a similar
maximum bead penetration.
Table 1 Comparison of drug
loading times for DC BeadM1
and DC Bead 100–300 lm
Loading time (mins) 30 60 120
Drug loading Bead size range (lm) % Drug loaded
37.5 mg/mL Dox 70–150 99.8 100.23 N/A
37.5 mg/mL Dox 100–300 97.89 100.22 N/A
50 mg/mL Iri 70–150 97.5 98.0 99.9
50 mg/mL Iri 100–300 97.1 98.5 100.01
Fig. 2 Representative images of 100–300 lm (top row a, c, and
e) and 70–150 lm (bottom row b, d, and f). Bland beads (a and b),
irinotecan loaded beads (c and d) and doxorubicin loaded beads
(e and f) appear similar except the smaller size range is more uniform
and smaller in diameter (scale bar each division 100 lm, total length
500 lm)
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3.4 Drug elution characteristics
Figure 5a shows that under the rapid elution conditions of
this in vitro test, complete elution of doxorubicin is
achieved over several hours with both the 100–300 lm
bead (half-life (time for 50 % elution) = 0.57 h) and
70–150 lm beads (half-life = 0.52 h) eluting at the same
rate. Irinotecan elution however, takes only around an hour
under the same conditions (half-life = 7.26 min) with the
100–300 lm bead size range eluting marginally slower
than the 70–150 lm beads (half-life 4.68 min) (Fig. 5b).
3.5 In vivo bead distribution
In order to gain an appreciation of how the 70–150 lm
beads might distribute within the vasculature in vivo, a
radiopaque version of this product was prepared and
compared to a corresponding radiopaque 100–300 lm
product, as shown in Fig. 6. 70–150 lm beads result in a
more distal embolisation; reaching the periphery of the
rabbit liver tissue. In contrast, 100–300 lm are located
more central in the liver. Both beads reached the tumour
but the 70–150 lm provided greater coverage of the tumor
periphery and some penetration into the tumor core.
4 Discussion
4.1 Study findings and the state of the art
Most of the published literature describes the use of DC
Bead in sizes ranges of 100–300 lm, 300–500 lm and
Fig. 3 Bead size distribution for various bead size ranges and with
drug loading. a Bead size distribution in 0.9 % saline shown as a
histogram for all DC Bead sizes (n = 1000). b Average bead
diameters of DC BeadM1 with 37.5 mg/mL doxorubicin (Dox) and
50 mg/mL irinotecan loading (n = 400)
Fig. 4 Quantification of in vitro bead penetration (drug loading
levels: 37.5 mg/mL doxorubicin and 50 mg/mL irinotecan)
Fig. 5 a Comparisons of doxorubicin elution (37.5 mg/mL loading)
for 70–150 and 100–300 lm size DC Bead sizes (n = 2). b Compar-
isons of irinotecan elution (50 mg/mL loading) for 70–150 and
100–300 lm size DC Bead sizes (n = 2)
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500–700 lm. Regardless of size, the use of this device
loaded with doxorubicin to treat HCC has yielded some
encouraging 4 [38] and 5 [39] year survival data. From a
physical perspective, as the size range becomes smaller, the
percent difference between the smallest and largest beads
within this population becomes increasingly large (Figs. 2,
3); hence, for the 500–700 lm range there is a 1.4- fold
difference but for the 100–300 lm range there is a three-
fold difference in the sizes of arteries that may be occluded.
We hypothesised that if this difference in the 100–300 lm
range could be refined to remove the larger sized bead
fraction, the resulting DEB would have greater distal
penetration. Similar to larger size ranges, the 70–150 lm
range was manufactured with a modified reverse suspen-
sion polymerisation process but this 100–300 lm product
was further sieved in order to remove the higher-end
diameter beads, whilst maintaining the lower size specifi-
cation limit that is identical to the current 100–300 lm size
range.
In this investigation drug loading of the 70–150 lm
range was observed to be faster than for the 100–300 lm
size range for both doxorubicin and irinotecan (see
Table 1), as anticipated by the overall increase in surface
area to volume ratio that arises as a consequence of its
smaller average bead diameter. Prior to clinical evaluation,
thorough bench testing was required in order to determine
if the physicomechanical properties of the 70–150 lm
beads were similar to conventional 100–300 lm bead size
range. From data such as that shown in Fig. 4 for instance,
it can be seen that both size ranges have the potential to
penetrate to the same maximum level of occlusion,
demonstrating that the smallest bead fraction of either size
range are both similar in size and compressive nature
(somewhat addressing potential safety concerns). Clearly,
the loading of either drug decreased the average bead
diameter, but resulted in a concomitant increase in the
resistance to compression [8, 10] that culminated in a
marginal increase in distal penetration. However, the larger
size range of 100–300 lm results in a greater distribution
in the level of penetration. This test demonstrates the
ability of the beads to compress, deform and occlude levels
below their nominal lowest bead diameter; this however, is
not directly translatable to the situation in vivo, as in this
in vitro penetration model the beads are compressed in a
quasi-uniaxial direction between two flat surfaces as
opposed to being deformed within a cylindrically-shaped
vessel. Furthermore, in vivo a large bead from the
100–300 lm size range may prematurely occlude a blood
vessel before the smaller beads within the size distribution
have the opportunity to penetrate to their nominal size. The
tighter size distribution of 70–150 lm limits the likelihood
of in vivo premature occlusion. This is demonstrated in this
study (Fig. 6) in which we have investigated the distribu-
tion in a tumour-bearing rabbit liver, where we see that the
100–300 lm beads have a tendency to occlude and accu-
mulate in the larger, proximal and more central hepatic
arteries, whereas the 70–150 lm beads are seen clearly
occupying the smaller, more distal and peripheral arteries
and those surrounding the tumour (Fig. 7).
Under pseudo-sink elution conditions, it was expected to
observe a relatively slow elution of doxorubicin from the
beads due to strong drug-bead and drug–drug interactions
[7], whilst irinotecan release should occur over a much
shorter period. Doxorubicin elution rates were similar for
both 70–150 lm and 100–300 lm beads when measured
under pseudo-sink conditions which is consistent with data
previously presented on the comparison of the systemic
pharmacokinetics of doxorubicin release from the
100–300 lm bead and 70–150 lm beads in a rabbit VX2
tumour model performed at Johns Hopkins University [40],
that showed blood plasma levels to be equivalent and low
compared to historical values generated for cTACE [41].
They reported a similar finding for the first 10 patients
treated with the 70–150 lm beads compared to historical
data from 500 to 700 lm beads [42], confirming that
in vivo there is less difference in the systemic exposure of
doxorubicin between different sized beads than that pre-
dicted by in vitro methodologies [43]. The Hopkins VX2
study also showed that both the number of beads present
and the doxorubicin concentration in the tumour were 2.6-
fold greater for the 70–150 lm beads compared to
100–300 lm beads. These data are consistent with the
work of Dreher et al. that demonstrated a *twofold
increase in drug coverage using a swine liver model ( [37],
Fig. 6 CT and microCT of 70–150 and 100–300 lm radiopaque
beads. 70–150 lm beads provide a more distal embolisation and
obtain greater tumour coverage. The box in the CT image demon-
strates the location of the tumour
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Fig. 8). The 70–150 lm beads therefore appear to offer the
enhanced locoregional drug delivery benefits of low sys-
temic drug exposure [13] with greater tumour
concentrations.
As there is a strong desire by treating physicians to
consistently deliver the full planned bead volume and
associated drug dose to often smaller and/or less vascular
tumours, the use of DEB sizes smaller than 100–300 lm
should allow access to a greater portion of the targeted
vascular volume and may achieve this goal, while at the
same time lead to a more distal embolisation. This rationale
is supported by data obtained from resected liver lesions
following DEBDOX which suggest that most of the
100–300 lm beads are confined to the tumour periphery
[44], the previously mentioned preclinical studies which
demonstrated the more distal occlusion and associated
greater drug coverage for 70–150 lm beads [37] and our
data presented here on comparative beads distributions in a
VX2 tumour model. More recently in the Spreafico study
of HCC patients undergoing DEB-TACE with 70–150 lm
beads as a bridge to transplant, they demonstrate histo-
logically that these small beads can penetrate deep within
the tumour, even in small nodules where the vasculature is
not as well developed [45]. In a study reported by Kelly
et al. comparing 70–150 lm beads to 100–300 lm beads
for the delivery of irinotecan to patients with hepatic
metastatic disease, they demonstrated that when using the
70–150 lm beads there was less premature vessel occlu-
sion and hence more of the drug dose administered, toge-
ther with a lower adverse event rate (Table 2, [46] ); a
finding confirmed in a recent propensity score matching
analysis of small versus large DEBIRI [47]. These data
validate the bench testing and preclinical data that the
70–150 lm beads have the ability to allow more volume of
beads to be delivered before stasis is reached and hence
more of the drug dose can be administered.
4.2 Review of current clinical safety and efficacy
data
Padia et al. recently reported a study of 61 patients with
HCC treated with either 100–300 lm (n = 39) or
300–500 lm (n = 22) LC BeadTM loaded with 50 mg of
doxorubicin. They found a significantly lower incidence of
Fig. 7 Comparison of the distribution of 70–150 lm (top) and
100–300 lm (bottom) radiopaque beads in embolised swine liver
tissue (sagittal (left) and coronal (right) views of the tissue sample).
Note that despite the same lower limit of bead size, the 70–150 lm
bead are able to penetrate down into the tiny vessels at the liver
capsule surface, whereas there is a clear bead-free margin at the
surface of the sample containing the 100–300 lm beads (unpublished
data from the study described in Ref. [37])
Fig. 8 Epifluorescent microscopy of liver tissue sections embolised
with 70–150 lm versus 100–300 lm doxorubicin loaded DC Bead
showing increased bead number, spatial distribution and drug
penumbra (left) and the corresponding comparison of the percentage
drug coverage (right, unpublished data from [37])
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postembolisation syndrome (PES, one of the commonest
side effects of transarterial embolisation and chemoem-
bolisation comprising of fever, nausea/vomiting and pain)
(P = 0.011) and fatigue (P = 0.025) after treatment in the
100–300 lm group (8 and 36 %) versus the 300–500 lm
group (40 and 70 %). The mean change in tumour size was
similar between the two groups based on WHO and EASL
criteria and similar rates of objective response (OR), but
there was a trend toward a higher incidence of EASL
complete response (CR) with 100–300 versus 300–500 lm
beads (59 vs. 36 %; P = 0.114) [48]. Such findings have
motivated others to assess the 70–150 lm beads to see if
even smaller beads improve outcomes further.
Spreafico et al. treated 45 consecutive patients with
HCC using 70–150 lm beads and obtained an OR rate
[CR ? partial response (PR)] of 77.7 % with a median
time to best response of 3 months (95 % confidence
interval 2–4). In 13 patients, the treatment served as a
bridge/downstaging to LT/surgery and pathological analy-
sis of the removed tumors showed that more than 90 %
necrosis was achieved in 10 of 28 nodules. The small beads
were well tolerated, and the grade 3/4 adverse event rate
was low (1 of 65 procedures) [45]. Justaniah et al. con-
ducted a retrospective analysis of three cohorts of HCC
patients treated with 100 mg of doxorubicin from two vials
of beads of different sizes: 300–500 and 500–700 lm
beads (n = 74, large bead group), 100–300 and
300–500 lm beads (n = 33, medium bead group) or
70–150 and 100–300 lm beads (n = 36, small bead group)
over a period spanning 2008–2013. They found CR rates
for patients treated with small beads were significantly
higher at 3 and 6 months than those treated with larger
beads [CR 34 vs. 73 vs. 92 % at 3 months (P\ 0.01) for
large, medium and small respectively]. At 9 and 12 months
the CR rates were no longer significant due to disease
progression (PD) in untreated areas [CR 27 vs. 63 vs. 72 %
(P = 0.06) and PD 21, 17 and 15 % respectively]. Heithaus
et al. recently reported on midterm outcomes from 94
DEB-TACE sessions using 70–150 lm beads in which
disease control (DC = CR ? PR ? SD) was achieved in
95 % of focal and 96 % of small tumors versus 61 % of
multifocal (P = 0.04) and 55 % of large tumors
(P = 0.0009). They concluded the treatment was safe with
no grade 4/4 complications, 88 % of patients discharged
within 24 h and demonstrated antitumoural response and
survival benefits [49]. Rao et al. demonstrated the safety
and feasibility of performing a DEB-TACE procedure in
31 consecutive patients treated with 70–150 lm beads, as
an outpatient procedure with same-day discharge for 88 %
of patients given their observations of decreased symptoms
of PES [50]. Yet there are reports in some studies with
70–150 lm beads that yielded increased PES relative to
100–300 lm beads (11 vs. 0 %), nausea (33 vs. 14 %),
fatigue (50 vs. 14 %) (all P[ 0.05) although hair loss was
significant (39 vs. 0 %, P = 0.01) [51]. Thus it is clear that
the technique of delivery is very important in determining
both outcome and tolerability of the treatment when using
smaller drug eluting bead products and more detailed
clinical investigation is warranted.
5 Conclusions
As clinical experience is mounting for the use of DEB for
the treatment of hepatic malignancies, techniques for bead
administration (e.g. ‘‘embo-light’’ (a near-stasis end-point
but with some residual forward flow) versus stasis [5] )
have advanced along with refinement of drug dose and
bead size selection. A number of other DEB technologies
have appeared on the market but it would be dangerous to
assume similar clinical performance without comparative
data, as each has unique chemistry and physical properties
that will influence their handling, administration,
embolization end-point, rate and extent of drug elution
(and hence ultimately drug bioavailability). This evolution
of clinical technique and device characteristics relies on the
iterative interaction between the bench and bedside. There
is sufficient evidence from a variety of animal models [10,
Table 2 Results from a study
comparing 70–150 lm beads to
100–300 lm beads for the
delivery of irinotecan to patients
with hepatic metastatic disease
(degree of occlusion determined
angiographically) [47]
N = 303 N = 34
DC Bead 100–300 lm DC BeadM1 70–150 lm
Dose delivered
\100 mg 77 % 18 %
100 mg 23 % 82 %
Degree of occlusion (%)
None 0 % 6 %
Partial 39 % 62 %
Near 26 % 29 %
Complete 35 % 3 %
Adverse events (%) 19 % 6 %
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41, 52–55], human PK studies [13, 14] and liver explant
evaluations [32, 44, 45, 56, 57] to support the fact that
DEBDOX and DEBIRI result in lower systemic drug
exposure and higher intratumoural drug concentrations
than achieved by hepatic arterial infusion or conventional
TACE. Although the optimal procedural conditions for
DEB administration however, have not yet been clearly
defined, a new DEB size range capable of an increased
distal volume (dose) penetration (70–150 lm) offers
potential for improved therapeutic outcomes. This smaller
and narrower size range provides a relatively similar drug
loading and elution profile in addition to the desired con-
sistent distal penetration. The availability of this product
and the data generated from its clinical use may start to
shed light on the optimum configuration required for
transcatheter therapy of hepatic malignancies using DEB.
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